[The value of plasma pro-gastrin-releasing peptide, cytokeratin 19-fragments and carcinoembryonic antigen in patients with lung cancer].

Yong Jian Chen*, Wei Dong Jin, Guang Yu Yang, Yong Lie Zhou

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

To evaluate the value of plasma ProGRP, CYFRA 21-1 and CEA in patients with lung cancer. The levels of plasma ProGRP, CYFRA 21-1 and CEA were detected in 85 healthy control, 49 benign lung diseases and 143 lung neoplasms. The levels of ProGRP in the patients with SCLC was monitored. The level of plasma ProGRP in SCLC (M 179.1 ng/ml) was significantly higher than adenocarcinoma (M 35.3 ng/ml), squamous-cell carcinoma (M 33.3 ng/ml), healthy control (M 35.6 ng/m) and benign lung diseases (M 33.3 ng/m), P < 0.001. The sensitivity and specificity for diagnosing SCLC by ProGRP were 60.6% and 95.0% respectively. In the effective treatment group, ProGRP reduced 45.9%, in the progression group, ProGRP increased 103.1%, P < 0.05. The level of CEA in the metastatic adenocarcinoma (M 10.22 ng/ml) was significantly higher than non-metastatic adenocarcinoma (M 3.85 ng/ml) and squamous cell carcinoma (M 2.56 ng/ml) (P < 0.01). The plasma ProGRP is a good indicator for diagnosing and evaluating cure effect in SCLC; the high expression of CEA is related to the metastatic adenocarcinoma.

Original languageEnglish (US)
Pages (from-to)381-383
Number of pages3
JournalZhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology
Volume25
Issue number5
StatePublished - Oct 1 2011

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of '[The value of plasma pro-gastrin-releasing peptide, cytokeratin 19-fragments and carcinoembryonic antigen in patients with lung cancer].'. Together they form a unique fingerprint.

Cite this